Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 6, 2024Journal of Clinical MedicineOpen Access

Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX–Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective–Prospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAntonio CoppolaGRGianna Franca RivoltaGQGabriele Quintavalle

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Coppola et al. (2024) studied this question.

synapsesocial.com/papers/68e7569cb6db6435876ceb2dhttps://doi.org/10.3390/jcm13051518
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial2014 · 180 citations
  2. 2Immunogenicity of Current and New Therapies for Hemophilia A2022 · 17 citations
  3. 3Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)2021 · 40 citations
  4. 4Humanistic burden of problem joints for children and adults with haemophilia2022 · 15 citations
  5. 5Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B2018 · 21 citations